Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more
Karyopharm Therapeutics Inc (KPTI) - Net Assets
Latest net assets as of September 2025: $-269.26 Million USD
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has net assets worth $-269.26 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($96.23 Million) and total liabilities ($365.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-269.26 Million |
| % of Total Assets | -279.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -280.55% |
| Growth Volatility | 89.65 |
Karyopharm Therapeutics Inc - Net Assets Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual net assets of Karyopharm Therapeutics Inc from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-292.93 Million | -57.47% |
| 2024-12-31 | $-186.02 Million | -36.57% |
| 2023-12-31 | $-136.21 Million | -717.76% |
| 2022-12-31 | $-16.66 Million | +79.09% |
| 2021-12-31 | $-79.67 Million | -257.62% |
| 2020-12-31 | $50.55 Million | +1.55% |
| 2019-12-31 | $49.77 Million | -72.83% |
| 2018-12-31 | $183.17 Million | +41.48% |
| 2017-12-31 | $129.46 Million | -20.20% |
| 2016-12-31 | $162.24 Million | -18.21% |
| 2015-12-31 | $198.37 Million | -4.08% |
| 2014-12-31 | $206.79 Million | +33.47% |
| 2013-12-31 | $154.93 Million | +655.78% |
| 2012-12-31 | $-27.88 Million | -120.35% |
| 2011-12-31 | $-12.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Karyopharm Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 174676500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.22 Million | % |
| Other Comprehensive Income | $71.00K | % |
| Other Components | $1.45 Billion | % |
| Total Equity | $-292.93 Million | 100.00% |
Karyopharm Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acres Commercial Realty Corp
NYSE:ACR
|
$126.82 Million |
|
Prime Mining Corp
OTCQX:PRMNF
|
$126.84 Million |
|
Priner Serviços Industriais S.A
SA:PRNR3
|
$126.86 Million |
|
Nabors Energy Transition Corp. II Class A Ordinary Shares
NASDAQ:NETD
|
$126.87 Million |
|
Genome & Company
KQ:314130
|
$126.77 Million |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
$126.75 Million |
|
SIMILARWEB LTD IS-01
F:63X
|
$126.74 Million |
|
Garofalo Health Care S.p.A
F:GHC
|
$126.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Karyopharm Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -186,017,000 to -292,926,000, a change of -106,909,000.
- Net loss of 196,039,000 reduced equity.
- Other comprehensive income increased equity by 427,000.
- Other factors increased equity by 88,703,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-196.04 Million | -66.92% |
| Other Comprehensive Income | $427.00K | +0.15% |
| Other Changes | $88.70 Million | +30.28% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Karyopharm Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-6.38 | $8.38 | x |
| 2012-12-31 | $-14.06 | $8.38 | x |
| 2013-12-31 | $383.02 | $8.38 | x |
| 2014-12-31 | $99.63 | $8.38 | x |
| 2015-12-31 | $83.54 | $8.38 | x |
| 2016-12-31 | $64.86 | $8.38 | x |
| 2017-12-31 | $42.31 | $8.38 | x |
| 2018-12-31 | $3.23 | $8.38 | x |
| 2019-12-31 | $0.80 | $8.38 | x |
| 2020-12-31 | $0.70 | $8.38 | x |
| 2021-12-31 | $-15.89 | $8.38 | x |
| 2022-12-31 | $-3.05 | $8.38 | x |
| 2023-12-31 | $-17.89 | $8.38 | x |
| 2024-12-31 | $-22.90 | $8.38 | x |
| 2025-12-31 | $-26.79 | $8.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Karyopharm Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -134.21%
- • Asset Turnover: 1.35x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -6783.55% | 0.02x | 0.00x | $-9.05 Million |
| 2012 | 0.00% | -2505.99% | 0.48x | 0.00x | $-13.10 Million |
| 2013 | -21.91% | -8771.83% | 0.00x | 1.02x | $-49.44 Million |
| 2014 | -36.64% | -33090.39% | 0.00x | 1.07x | $-96.46 Million |
| 2015 | -59.58% | -47272.40% | 0.00x | 1.09x | $-138.02 Million |
| 2016 | -67.54% | -71153.90% | 0.00x | 1.11x | $-125.80 Million |
| 2017 | -99.63% | -8036.39% | 0.01x | 1.39x | $-141.93 Million |
| 2018 | -97.40% | -588.10% | 0.09x | 1.86x | $-196.72 Million |
| 2019 | -400.99% | -488.08% | 0.14x | 5.93x | $-204.57 Million |
| 2020 | -388.31% | -181.59% | 0.35x | 6.19x | $-201.33 Million |
| 2021 | 0.00% | -59.14% | 0.69x | 0.00x | $-116.12 Million |
| 2022 | 0.00% | -105.23% | 0.44x | 0.00x | $-163.63 Million |
| 2023 | 0.00% | -97.99% | 0.61x | 0.00x | $-129.48 Million |
| 2024 | 0.00% | -52.62% | 0.88x | 0.00x | $-57.82 Million |
| 2025 | 0.00% | -134.21% | 1.35x | 0.00x | $-166.75 Million |
Industry Comparison
This section compares Karyopharm Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Karyopharm Therapeutics Inc (KPTI) | $-269.26 Million | 0.00% | N/A | $126.81 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |